| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4103-5MG | N6022 | 5mg | $126.00 | |
| GBM-4103-25MG | N6022 | 25mg | $431.00 |
| Bioassays Specification | |
| Bio-Activity | S-Nitrosogluthione reductase inhibitor |
| Chemical Name | 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid |
| Function / Pharmacology | N6022 is a potent and reversible inhibitor of S-nitrosoglutathione reductase (GSNOR) – IC50 = 20 nM1, 8 nM2. It demonstrated significant efficacy in a mouse models of ovalbumin-induced asthma, chronic obstructive pulmonary disease, and irritable bowel syndrome. N6022 was able to attenuate experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis) via selective inhibition of pro-inflammatory CD4+ cells (TH1/TH17) while upregulating anti-inflammatory subsets of CD4+ cells (TH2/Treg) without causing lymphopenia.3 |
| CAS# | 1208315-24-5 |
| MW | 414.5 |
| Molecular Formula | C24H22N4O3 |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Sun et al. (2011), Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases; ACS Med. Chem. Lett. 2 402 2) Green et al. (2012), Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase; Biochemistry 51 2157 3) Saxena et al. (20198), S-Nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis; Free Radic. Biol. Med. 121 57 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | S-Nitrosogluthione reductase inhibitor |
| Chemical Name | 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid |
| Function / Pharmacology | N6022 is a potent and reversible inhibitor of S-nitrosoglutathione reductase (GSNOR) – IC50 = 20 nM1, 8 nM2. It demonstrated significant efficacy in a mouse models of ovalbumin-induced asthma, chronic obstructive pulmonary disease, and irritable bowel syndrome. N6022 was able to attenuate experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis) via selective inhibition of pro-inflammatory CD4+ cells (TH1/TH17) while upregulating anti-inflammatory subsets of CD4+ cells (TH2/Treg) without causing lymphopenia.3 |
| CAS# | 1208315-24-5 |
| MW | 414.5 |
| Molecular Formula | C24H22N4O3 |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Sun et al. (2011), Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases; ACS Med. Chem. Lett. 2 402 2) Green et al. (2012), Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase; Biochemistry 51 2157 3) Saxena et al. (20198), S-Nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis; Free Radic. Biol. Med. 121 57 |
| Protein Specification | |
| Purity | >98% |
